Literature DB >> 33932293

Low-density neutrophils in chronic graft versus host disease (cGVHD) are primarily immature CD10- and enhance T cell activation.

Nick C Matthews1, Charlotte S Burton1, Arun Alfred1.   

Abstract

Chronic graft-versus-host disease (cGVHD) is a frequent complication of allogeneic haematopoietic stem cell transplantation. Low density neutrophils (LDNs) in autoimmunity, which shares disease features with cGVHD, are proinflammatory, whereas those in cancer and sepsis suppress T cell immunity. Mature LDNs can be distinguished from immature LDNs on the basis of expression of CD10 and suppressive neutrophils can be identified using lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) expression. The functionality of LDNs in cGVHD has not been specifically investigated. Here, we have determined the relative contribution of immature and mature neutrophils to LDNs in cGVHD and assessed whether these were suppressive or potentially proinflammatory. Peripheral blood LDNs and normal density neutrophils (NDNs) from 30 cGVHD patients and NDNs from 10 healthy controls (HCs) were immunophenotyped by flow cytometry. The ability of LDNs and NDNs to influence T cell proliferation and cytokine production in co-cultures was quantified. To further characterize LDNs, their propensity to undergo constitutive apoptosis and differentiate ex vivo was assessed. LDNs were elevated in cGVHD versus HCs, heterogeneous in phenotype, with a predominance of immature CD10- cells in most patients, but some mature CD10+ LOX-1+ LDNs were also detected. LDNs enhanced autologous T cell proliferation, interleukin (IL)-6 and interferon (IFN)-γ production. LDN, but not NDN, CD10 expression was inversely correlated with LOX-1, which correlated with IL-6 production. LDNs resisted apoptosis and differentiated into antigen-presenting/neutrophil-hybrid-like cells, which co-expressed major histocompatibility complex (MHC) class II HLA-DR and immuno-inhibitory programmed cell death ligand 1 (PD-L1), but did not suppress T cell proliferation. These data suggest LDNs in cGVHD are predominantly immature, proinflammatory and may have pathogenic potential.
© 2021 British Society for Immunology.

Entities:  

Keywords:  CD10; T cells; chronic graft-versus-host disease; lectin-like oxidized lipoprotein receptor-1; neutrophils

Mesh:

Substances:

Year:  2021        PMID: 33932293      PMCID: PMC8274189          DOI: 10.1111/cei.13612

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   5.732


  53 in total

1.  Importance of culturing primary lymphocytes at physiological oxygen levels.

Authors:  Kondala R Atkuri; Leonard A Herzenberg; Anna-Kaisa Niemi; Tina Cowan; Leonore A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

Review 2.  Human neutrophils in the saga of cellular heterogeneity: insights and open questions.

Authors:  Patrizia Scapini; Olivia Marini; Cristina Tecchio; Marco A Cassatella
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

3.  A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases.

Authors:  Helena Janols; Caroline Bergenfelz; Roni Allaoui; Anna-Maria Larsson; Lisa Rydén; Sven Björnsson; Sabina Janciauskiene; Marlene Wullt; Anders Bredberg; Karin Leandersson
Journal:  J Leukoc Biol       Date:  2014-06-13       Impact factor: 4.962

4.  Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.

Authors:  Stephan Lang; Kirsten Bruderek; Cordelia Kaspar; Benedikt Höing; Oliver Kanaan; Nina Dominas; Timon Hussain; Freya Droege; Christian Eyth; Boris Hadaschik; Sven Brandau
Journal:  Clin Cancer Res       Date:  2018-06-18       Impact factor: 12.531

5.  Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties.

Authors:  Sven Brandau; Sokratis Trellakis; Kirsten Bruderek; Dominik Schmaltz; Gabriele Steller; Motaz Elian; Henrik Suttmann; Marcus Schenck; Jürgen Welling; Peter Zabel; Stephan Lang
Journal:  J Leukoc Biol       Date:  2010-11-24       Impact factor: 4.962

6.  Suppression of T-cell functions by human granulocyte arginase.

Authors:  Markus Munder; Henriette Schneider; Claudia Luckner; Thomas Giese; Claus-Dieter Langhans; Jose M Fuentes; Pascale Kropf; Ingrid Mueller; Armin Kolb; Manuel Modolell; Anthony D Ho
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

7.  Neutrophil kinetics in man.

Authors:  J T Dancey; K A Deubelbeiss; L A Harker; C A Finch
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

Review 8.  Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology.

Authors:  Claudia A Dumitru; Katrin Moses; Sokratis Trellakis; Stephan Lang; Sven Brandau
Journal:  Cancer Immunol Immunother       Date:  2012-06-13       Impact factor: 6.968

9.  Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer.

Authors:  Evgeniy B Eruslanov; Pratik S Bhojnagarwala; Jon G Quatromoni; Tom Li Stephen; Anjana Ranganathan; Charuhas Deshpande; Tatiana Akimova; Anil Vachani; Leslie Litzky; Wayne W Hancock; José R Conejo-Garcia; Michael Feldman; Steven M Albelda; Sunil Singhal
Journal:  J Clin Invest       Date:  2014-11-10       Impact factor: 14.808

10.  Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus.

Authors:  Saifur Rahman; Divya Sagar; Richard N Hanna; Yaima L Lightfoot; Pragnesh Mistry; Carolyne K Smith; Zerai Manna; Sarfaraz Hasni; Richard M Siegel; Miguel A Sanjuan; Roland Kolbeck; Mariana J Kaplan; Kerry A Casey
Journal:  Ann Rheum Dis       Date:  2019-04-30       Impact factor: 19.103

View more
  1 in total

Review 1.  Low-Density Granulocytes in Immune-Mediated Inflammatory Diseases.

Authors:  Xin Ning; Wen-Ming Wang; Hong-Zhong Jin
Journal:  J Immunol Res       Date:  2022-01-31       Impact factor: 4.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.